abstract |
The invention discloses the application of miRNA in predicting the sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy. The miRNA includes miR-4291, miR-449a, and/or miR-663. After verification, it is found that the miRNA is used for predicting Markers of the sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy have high diagnostic performance, which can assist clinicians in judging the sensitivity or responsiveness of subjects to platinum-containing double-drug chemotherapy, and then screen out the sensitivity or reactivity of platinum-containing double-drug chemotherapy. Drug chemotherapy-sensitive lung adenocarcinoma patients to achieve individualized treatment. |